The prospects and perils of reclassifying cannabis as a less dangerous controlled substance
The impending decision by the Drug Enforcement Administration (DEA) to reclassify cannabis as a less dangerous controlled substance marks a significant shift in federal drug policy. Reliable reports confirming the DEA’s intent to move cannabis from a Schedule I drug — the strictest category of controlled substances — to Schedule III all but assure this outcome. The implications are profound, bringing obvious benefits but also potential drawbacks that may be consequential enough to require congressional action.
First, drugs currently in Schedule I are those deemed to have no “medically accepted uses” and a high potential for abuse. A move to Schedule III serves as a recognition of cannabis’ medicinal value and relatively low potential for abuse compared to substances in Schedule I, like heroin, and Schedule II, like fentanyl. This acknowledgment aligns with mounting scientific evidence supporting the therapeutic utility of cannabis for various medical conditions. Rescheduling could lead to increased access to medical cannabis for patients suffering from chronic pain, epilepsy, PTSD and other ailments, potentially improving their quality of life, particularly those living in one of the 13 states that have yet to authorize legal cannabis sales in any form. Moreover, by easing barriers to medical research, the move may lead to an increase in the number of conditions cannabis may treat, as well as improvements or innovations in its effects, safety and efficacy.
In the immediate term, the cannabis industry would be the greatest beneficiary of the move. By placing cannabis in Schedule III, cannabis businesses would gain increased access to traditional banking services and investment capital. More importantly, perhaps, a move to Schedule III would allow licensed cannabis businesses to deduct business expenses from their tax burden, an allowance afforded to other lawful industries. The increased investment and reduced costs could increase financial stability and stimulate spending within the industry, leading to more jobs, reinvestment into local economies and increased tax revenue.
Lastly, one little-discussed positive effect of reclassifying cannabis is the future impact it may have on other controlled substances, such as psychedelics. Traditionally, federal agencies have used FDA approval as proof that a drug has “medically accepted uses.” In fact, in previous attempts to reschedule cannabis, both the FDA and the DEA determined that only FDA-approved drugs with cannabis components could be moved to a lower schedule, not the entire plant. That federal health and drug agencies now recommend moving the entire cannabis plant to Schedule III signals a significant shift that could open the door for reform regarding other Schedule I substances, such as psilocybin and MDMA.
Despite the positive impact of moving cannabis to Schedule III, there are also possible drawbacks. For one, the move does not “legalize” cannabis at the federal level nor would it bring state-authorized cannabis industries into compliance with federal law, leaving consumers and businesses open to criminal penalties. While the move would reduce schedule-specific penalties, it would not eliminate them or adjust penalties that apply specifically to marijuana, such as quantity-based mandatory-minimum sentencing requirements.
Similarly, while Schedule III drugs, unlike Schedule I, can be lawfully dispensed, a valid prescription is required. Traditionally, drugs in Schedule III — like anabolic steroids and ketamine — may only be legally prescribed after receiving FDA approval. How feasible this approval process might be will depend largely on how the FDA chooses to exercise its regulatory authority over cannabis products. If the FDA opts to treat cannabis like other pharmaceutical drugs, the approval process for which can take up to 15 years and cost over $1 billion, it would likely devastate state cannabis markets and drastically reduce the products available to consumers. FDA may choose to adopt an alternative pathway for cannabis product approval that would better balance requirements for efficacy and safety against consumer access, but this would likely require action by Congress.
The prospects and perils of cannabis’s reclassification are profound. It may unlock significant benefits for patients, businesses and the broader economy. Yet, it does not address the ongoing conflict between state and federal law, continues to leave consumers and state-authorized cannabis markets vulnerable to federal prosecution, and raises a host of new complexities surrounding regulatory oversight of cannabis.
In this pivotal moment, it is increasingly evident that responsibility for resolving the ongoing uncertainties surrounding cannabis’ legal status ultimately rests with Congress. If anything, the move to reschedule cannabis demonstrates a need for and interest in comprehensive drug reform. An easy first step that could resolve many of these complexities regarding cannabis would be for Congress to simply remove it from the list of controlled substances entirely and leave its regulation to the states.
Michelle Minton is a senior policy analyst at the Reason Foundation.
Date: |
Filter
-
Cannabis stocks rise as U.S. moves to reclassify pot as less dangerous
Cannabis companies including Cresco Labs, Trulieve and Ayr Wellness post solid gainsMarketWatch - Business -
Justice Department formally moves to reclassify marijuana as a less dangerous drug in historic shift
The Justice Department has formally moved to reclassify marijuana as a less dangerous drug, a historic shift in generations of U.S. drug policyABC News - Health -
Justice Department formally moves to reclassify marijuana as a less dangerous drug in a historic shift in US drug policy
Justice Department formally moves to reclassify marijuana as a less dangerous drug in a historic shift in US drug policyABC News - Health -
Formal Move to Reclassify Marijuana as a Less Dangerous Drug Marks Huge Policy Shift
As the Justice Department acts, major marijuana company stocks continue to rebound.Inc. - Business -
Biden formally moves to reclassify marijuana
Click in for more news from The Hill {beacon} Health Care Health Care The Big Story Biden announces DOJ marijuana move The Justice Department (DOJ) took a major step towards rescheduling marijuana, formally starting the process to move the ...The Hill - Politics - Joe Biden -
DOJ releases proposed rule to reclassify marijuana
The Biden administration announced Thursday that it's officially moving with a proposal to reschedule marijuana from Schedule 1 to Schedule 3.ABC News - Top stories -
Biden announces 'major step' toward reclassifying marijuana
The Biden administration announced Thursday it had initiated the formal rulemaking process to reschedule marijuana to Schedule III from its Schedule I designation that it has held for more than 50 years. The announcement follows the Department of ...The Hill - Politics - Joe Biden -
Kharkiv fighting difficult but under control - Zelensky
Yahoo News - World - Ukraine -
Snag An Xbox Wireless Controller For $36 At Verizon
If you act fast, you can grab a new Xbox wireless controller for just $36 from Verizon. Normally, a new Xbox controller costs $60, so you're saving 40% on a new gamepad if you use this deal. The offer is available to anyone--you do not need to be ...GameSpot - Tech -
France Works to Regain Control of Parts of New Caledonia
Yahoo News - World
More from The Hill
-
Trump hits Biden for blaming 'disaster' inflation on shrinking size of Snickers Bars
Former President Trump criticized President Biden's handling of inflation in a late-night social media rant, joking that he is blaming his "economic disaster" on the shrinking size of Snickers Bars. In back-to-back Truth Social posts late Friday ...The Hill - Politics - Joe Biden -
Sunday shows preview: Biden-Trump agree to debate; House Oversight hearing gets heated
President Biden and former President Trump agreed to take the debate stage later this year. as the two prepare for a rematch in November. As the 2024 election inches closer, the decision to go one-on-one will likely be a focus of this week's ...The Hill - Politics - Joe Biden -
Five things to know about Biden’s controversial retirement rule
The Biden administration finalized a rule cracking down on retirement advice last month that one Democrat and Republicans are already pushing to overturn. Here’s what you need to know about the Retirement Security Rule: How the rule works The ...The Hill - Politics - Joe Biden -
Latest Houthi strike in Red Sea hits oil tanker: US officials
The latest attack by Yemen's Houthi rebels in the Red Sea struck a Greek-owned and operated oil tanker with a ballistic missile early Saturday, according to U.S. officials. The Iranian-backed group hit the oil tanker Wind at around 1 a.m. local ...The Hill - Politics -
Suspect to remain behind bars after failed assassination attempt on Slovak prime minister
The man accused of attempting to assassinate Slovak Prime Minister Robert Fico has been ordered to remain behind bars, officials said. The Specialized Criminal Court in Slovakia ordered the suspect to be detained after prosecutors said they were ...The Hill - Politics